| VIS ID | Virus | Ensembl ID | Gene Type | Target Gene | Oncogene | Tumor Suppressor Gene | NCBI ID | Uniprot ID |
|---|---|---|---|---|---|---|---|---|
| TVIS10043128 | HBV | ENSG00000148053.18 | protein_coding | NTRK2 | Yes | No | 4915 | Q16620 Q548C2 Q5VWE5 |
| TVIS30085636 | HIV | ENSG00000148053.18 | protein_coding | NTRK2 | Yes | No | 4915 | Q16620 Q548C2 Q5VWE5 |
| TVIS30081400 | HIV | ENSG00000148053.18 | protein_coding | NTRK2 | Yes | No | 4915 | Q16620 Q548C2 Q5VWE5 |
| TVIS30071222 | HIV | ENSG00000148053.18 | protein_coding | NTRK2 | Yes | No | 4915 | Q16620 Q548C2 Q5VWE5 |
| TVIS20063893 | HPV | ENSG00000148053.18 | protein_coding | NTRK2 | Yes | No | 4915 | Q16620 Q548C2 Q5VWE5 |
| TVIS20036275 | HPV | ENSG00000148053.18 | protein_coding | NTRK2 | Yes | No | 4915 | Q16620 Q548C2 Q5VWE5 |
| TVIS20042854 | HPV | ENSG00000148053.18 | protein_coding | NTRK2 | Yes | No | 4915 | Q16620 Q548C2 Q5VWE5 |
| TVIS20067369 | HPV | ENSG00000148053.18 | protein_coding | NTRK2 | Yes | No | 4915 | Q16620 Q548C2 Q5VWE5 |
| TVIS20045438 | HPV | ENSG00000148053.18 | protein_coding | NTRK2 | Yes | No | 4915 | Q16620 Q548C2 Q5VWE5 |
| TVIS20070213 | HPV | ENSG00000148053.18 | protein_coding | NTRK2 | Yes | No | 4915 | Q16620 Q548C2 Q5VWE5 |
Target Gene Table
▼
TCGA Plot Options
▼
Drug Information
▼
| Gene | NTRK2 |
|---|---|
| DrugBank ID | DB11986 |
| Drug Name | Entrectinib |
| Target ID | BE0003605 |
| UniProt ID | Q16620 |
| Regulation Type | inhibitor |
| PubMed IDs | 30050303; 26457764; 26939704; 30425456 |
| Citations | Liu D, Offin M, Harnicar S, Li BT, Drilon A: Entrectinib: an orally available, selective tyrosine kinase inhibitor for the treatment of NTRK, ROS1, and ALK fusion-positive solid tumors. Ther Clin Risk Manag. 2018 Jul 20;14:1247-1252. doi: 10.2147/TCRM.S147381. eCollection 2018.@@Rolfo C, Ruiz R, Giovannetti E, Gil-Bazo I, Russo A, Passiglia F, Giallombardo M, Peeters M, Raez L: Entrectinib: a potent new TRK, ROS1, and ALK inhibitor. Expert Opin Investig Drugs. 2015;24(11):1493-500. doi: 10.1517/13543784.2015.1096344. Epub 2015 Oct 12.@@Ardini E, Menichincheri M, Banfi P, Bosotti R, De Ponti C, Pulci R, Ballinari D, Ciomei M, Texido G, Degrassi A, Avanzi N, Amboldi N, Saccardo MB, Casero D, Orsini P, Bandiera T, Mologni L, Anderson D, Wei G, Harris J, Vernier JM, Li G, Felder E, Donati D, Isacchi A, Pesenti E, Magnaghi P, Galvani A: Entrectinib, a Pan-TRK, ROS1, and ALK Inhibitor with Activity in Multiple Molecularly Defined Cancer Indications. Mol Cancer Ther. 2016 Apr;15(4):628-39. doi: 10.1158/1535-7163.MCT-15-0758. Epub 2016 Mar 3.@@Pacenta HL, Macy ME: Entrectinib and other ALK/TRK inhibitors for the treatment of neuroblastoma. Drug Des Devel Ther. 2018 Oct 23;12:3549-3561. doi: 10.2147/DDDT.S147384. eCollection 2018. |
| Groups | Approved; Investigational |
| Direct Classification | Phenylpiperazines |
| SMILES | CN1CCN(CC1)C1=CC=C(C(=O)NC2=NNC3=CC=C(CC4=CC(F)=CC(F)=C4)C=C23)C(NC2CCOCC2)=C1 |
| Pathways | |
| PharmGKB | |
| ChEMBL | CHEMBL1983268 |
